The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.

• Drug: topiramate
• Drug: phentermine

Inclusion Criteria:

• Obese adults
• Body mass index between 30.0 and 42.0 kg/m2 (inclusive)
• Medically healthy with no clinically significant results of screening exams

Exclusion Criteria:

• History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
• History of glaucoma or increased intraocular pressure
• History of kidney stones
• Cholelithiasis or cholecystitis within 6 months
• Cardiovascular event within 6 months
• Obesity of known genetic or endocrine origin
• Recent weight instability
• Use of Very Low Calorie diet or participation in organized weight loss program within 3 months
• Systolic blood pressure > 150 or diastolic > 95 mm Hg
• Positive urine drug or alcohol screen
• Positive serology for HIV, HBV, or HCV
• History of alcoholism or drug abuse
• History of significant psychiatric disease, current depression of moderate or greater severity, any history of suicidal ideation
• Hypersensitivity to study drug or related compounds
• Use of prescription or OTC medication other than hormonal contraceptive within 14 days prior to first dosing with study drug
• Blood donation or significant blood loss within 56 days or plasma donation within 7 days prior to first dosing with study drug
• Women who are pregnant or lactating
• Hemoglobin < 12 g/dL
• Use of tobacco or nicotine-containing products within 6 months